Sprout Pharmaceuticals Addyi (Flibanserin) Maker Named Top 10 Most Influential Health Company by TIME 2026

Key Takeaways

• TIME named Sprout Pharmaceuticals among 10 most influential global health and life science companies for 2026
• Recognition follows FDA approval of expanded indication for Addyi (flibanserin) in December 2025
• Company achieved record growth with increasing prescriber adoption and expanded payer coverage

---

Sprout Pharmaceuticals, the maker of women’s sexual health treatment Addyi (flibanserin), has been recognized by TIME magazine as one of the 10 most influential health and life science companies globally for 2026, announced April 29, 2026.

The Raleigh, North Carolina-based pharmaceutical company earned this prestigious recognition following a period of significant momentum, including record-setting growth, expanding prescriber adoption, and increasing insurance coverage for its flagship treatment.

FDA Approval Drives Company Growth

The recognition comes after a defining period for Sprout, highlighted by the U.S. Food and Drug Administration’s approval of an expanded indication for Addyi in December 2025. This regulatory milestone has positioned the company among biotech’s most prominent names in the sexual health sector.

Addyi, originally approved by the FDA in 2015, was the first FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The recent expanded indication represents a significant advancement in women’s sexual health treatment options.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Industry Recognition

Sprout’s inclusion in TIME’s exclusive list reflects the company’s growing influence in addressing unmet medical needs in women’s health. The recognition underscores the pharmaceutical industry’s increasing focus on sexual health as a critical component of overall wellness.

The company’s achievement is particularly notable given the competitive landscape of the life sciences industry, where only 10 organizations globally received this distinction for their role in shaping the future of health and medicine.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Expanding Access and Adoption

The company’s success has been driven by multiple factors, including improved prescriber education, enhanced patient access programs, and expanded insurance coverage. These initiatives have contributed to increased adoption of Addyi among healthcare providers treating women with sexual health concerns.

This recognition positions Sprout Pharmaceuticals as a key player in the evolving landscape of women’s health pharmaceuticals, particularly in the underserved area of female sexual dysfunction treatment.

---

Frequently Asked Questions

What is Addyi (flibanserin) used to treat?

Addyi is FDA-approved to treat hypoactive sexual desire disorder (HSDD) in premenopausal women, addressing low sexual desire that causes distress.

When did the FDA approve the expanded indication for Addyi?

The FDA approved an expanded indication for Addyi in December 2025, though specific details of the expansion were not disclosed in the announcement.

How significant is TIME’s recognition for pharmaceutical companies?

TIME’s list of 10 most influential health companies is highly prestigious, recognizing only organizations globally that are shaping the future of health and life sciences.

Related coverage

• Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
• Eli Lilly pipeline and deals: GLP-1, vaccines, and 2026 outlook
• Eli Lilly raises 2026 revenue guidance on Mounjaro demand